Testing Tezampanel for opioid withdrawal during inpatient care
About this title
Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder
Read the official source — NCT06538558Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
What will I do during this study?
Participants stay at the research centre for seven days. They receive tezampanel or placebo (an inactive comparison treatment) daily on days 2 to 7 while the team monitors withdrawal symptoms, safety and drug levels. The study is a dose-escalation trial with several participant cohorts.
- Listed locations
- IndianapolisSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Participation duration
- 7-day inpatient stay
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 40
- Sponsor
- Proniras Corporation
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06538558
- Official title
Show the full official title
A Phase I, Single-Center, Single-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Pharmacokinetics and Efficacy of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder
Recruitment & locations
Indianapolis
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Proniras Corporation.
Does this study involve medication?
Yes. The study involves medication, including Tezampanel and Placebo.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
